Breast Cancer Registry

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by iOMEDICO AG
Sponsor:
Collaborators:
Arbeitskreis Klinische Studien
Arbeitsgemeinschaft fur Internistische Onkologie
Information provided by (Responsible Party):
iOMEDICO AG
ClinicalTrials.gov Identifier:
NCT01351584
First received: May 9, 2011
Last updated: July 9, 2014
Last verified: July 2014

May 9, 2011
July 9, 2014
February 2007
December 2014   (final data collection date for primary outcome measure)
Course of Antineoplastic Treatment [ Time Frame: 5 years ] [ Designated as safety issue: No ]
Course of Antineoplastic Treatment [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT01351584 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Breast Cancer Registry
Clinical Registry to Present Treatment and Sequences of Treatments in Routine Practice in Germany

The registry aims to collect and analyse information on the antineoplastic treatment of breast cancer in daily routine practice in Germany. The registry will follow up patients for three years. It will identify common sequences of treatments used as well as changes in the treatment of the disease. The impact of nutrition (MaNut) and physical activity (MaFit) on the course of the adjuvant disease will be examined, as well as long-term side effects of adjuvant treatment (MaTox). Health-related quality of life will be analysed during the course of the treatment (MaLife). Based on the available data a prognostic score will be developed.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Breast cancer patients undergoing antineoplastic or antihormonal therapy.

Breast Cancer
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
4500
December 2019
December 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Breast cancer
  • 18 years and older
  • Antineoplastic or antihormonal treatment

Exclusion Criteria:

  • No breast cancer
  • Below 18 years
  • No antineoplastic or antihormonal treatment
Female
18 Years and older
No
Contact: Lisa Kruggel +49 761 15242 - 0 info@iomedico.com
Contact: Holger Hartmann, PhD +49 761 15242 - 0 info@iomedico.com
Germany
 
NCT01351584
IOM TMK, Tumorregister Mammakarzinom
No
iOMEDICO AG
iOMEDICO AG
  • Arbeitskreis Klinische Studien
  • Arbeitsgemeinschaft fur Internistische Onkologie
Study Chair: Hans Tesch, MD
iOMEDICO AG
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP